Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection.
Body Mass Index
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Coinfection
Cross-Sectional Studies
Elasticity Imaging Techniques
Fatty Liver
/ diagnostic imaging
Female
HIV
/ growth & development
HIV Infections
/ diagnostic imaging
Hepacivirus
/ growth & development
Hepatitis C, Chronic
/ diagnostic imaging
Humans
Liver
/ diagnostic imaging
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Factors
Spain
/ epidemiology
Triglycerides
/ blood
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 04 2020
21 04 2020
Historique:
received:
15
11
2019
accepted:
17
02
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Hepatic steatosis (HS) is frequently observed in HIV-infected patients. It is not known whether HIV infection is an independent risk factor for HS development. We aimed to analyze whether HIV coinfection was associated with a higher frequency of HS in patients with chronic hepatitis C. This was a retrospective cross-sectional study. 574 subjects with chronic hepatitis C virus (HCV) infection were included, 246 (43%) of them coinfected with HIV. All of them underwent transient elastography with controlled attenuation parameter (CAP) measurement. HS was defined as CAP ≥ 248 dB/m. 147 individuals (45%) showed HS in the HCV-monoinfected group and 100 (40.7%) in the HIV/HCV-coinfected group (p = 0.318). HS was associated with body mass index (BMI) [<25 Kg/m
Identifiants
pubmed: 32317646
doi: 10.1038/s41598-020-62671-y
pii: 10.1038/s41598-020-62671-y
pmc: PMC7174281
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Triglycerides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6736Références
Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diab. Endocrinol. 2, 901–910 (2014).
doi: 10.1016/S2213-8587(14)70032-4
Takahashi, H. et al. Biphasic effect of alcohol intake on the development of fatty liver disease. J. Gastroenterol. 50, 1114–1123 (2015).
doi: 10.1007/s00535-015-1058-z
Goossens, N. & Negro, F. Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. Rev. Recent Clin. Trials 9, 204–209 (2015).
doi: 10.2174/1574887109666141216101939
Leandro, G. et al. Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology 130, 1636–1642 (2006).
doi: 10.1053/j.gastro.2006.03.014
Diehl, A. M. & Day, C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N. Engl. J. Med. 377, 2063–2072 (2017).
doi: 10.1056/NEJMra1503519
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
doi: 10.1002/hep.28431
Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).
doi: 10.1038/nrgastro.2013.41
Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
doi: 10.1002/hep.29367
Maurice, J. B. et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 31, 1621–1632 (2017).
doi: 10.1097/QAD.0000000000001504
van Welzen, B. J., Mudrikova, T., El Idrissi, A., Hoepelman, A. I. M. & Arends, J. E. A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing? Infect. Dis. Ther. 8, 33–50 (2019).
doi: 10.1007/s40121-018-0229-7
Demir, M., Lang, S. & Steffen, H.-M. Nonalcoholic fatty liver disease - current status and future directions. J. Dig. Dis. 16, 541–557 (2015).
doi: 10.1111/1751-2980.12291
Rafiq, N. et al. Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver. Clin. Gastroenterol. Hepatol. 7, 234–238 (2009).
doi: 10.1016/j.cgh.2008.11.005
Vernon, G., Baranova, A. & Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285 (2011).
doi: 10.1111/j.1365-2036.2011.04724.x
Macías, J. et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 28, 1279–87 (2014).
doi: 10.1097/QAD.0000000000000248
Mohr, R. et al. Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Medicine (Baltimore). 97, e0462 (2018).
doi: 10.1097/MD.0000000000010462
Sulyok, M. et al. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study. Eur. J. Gastroenterol. Hepatol. 27, 679–85 (2015).
doi: 10.1097/MEG.0000000000000339
Vuille-Lessard, É. et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS 30, 2635–2643 (2016).
doi: 10.1097/QAD.0000000000001241
Price, J. C. et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am. J. Gastroenterol. 109, 695–704 (2014).
doi: 10.1038/ajg.2014.32
Aepfelbacher, J. A. et al. Increased Prevalence of Hepatic Steatosis in Young Adults with Life-long HIV. J. Infect. Dis., https://doi.org/10.1093/infdis/jiz096 (2019).
Vodkin, I., Valasek, M. A., Bettencourt, R., Cachay, E. & Loomba, R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment. Pharmacol. Ther. 41, 368–378 (2015).
doi: 10.1111/apt.13052
Machado, M. V., Oliveira, A. G. & Cortez-Pinto, H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors. Hepatology 52, 71–78 (2010).
doi: 10.1002/hep.23619
Pembroke, T. et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J. Hepatol. 67, 801–808 (2017).
doi: 10.1016/j.jhep.2017.05.011
Sansom, S. E. et al. Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic. Open Forum Infect. Dis. 6, ofz099 (2019).
doi: 10.1093/ofid/ofz099
Browning, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–95 (2004).
doi: 10.1002/hep.20466
Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022–1030 (2017).
doi: 10.1016/j.jhep.2016.12.022
Recio, E. et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur. J. Gastroenterol. Hepatol. 25, 905–911 (2013).
doi: 10.1097/MEG.0b013e32835f4c3d
Neukam, K. et al. Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Eur. J. Gastroenterol. Hepatol. 22, 801–807 (2010).
doi: 10.1097/MEG.0b013e328331a5d0
Corrao, G. & Aricò, S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27, 914–9 (1998).
doi: 10.1002/hep.510270404